Clinical Trial Update: A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated atomoxetine (Strattera) for Attention Deficit Hyperactivity Disorder. Results were posted on 2009-12-31 by sponsor Eli Lilly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• STRATTERA (Atomoxetine hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2009-12-31